1
Clinical Trials associated with Claudin18.2-Targeted Activated DC(Frontiergate Biopharm) / RecruitingEarly Phase 1IIT Exploratory Clinical Study of Combined Claudin18.2-Targeted Activated DC and CAR-T Therapy in Patients With Advanced Pancreatic Cancer
This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2 Targeted Activated DC combined with CAR-T therapy in patients with Advanced Pancreatic Cancer.
This combination therapy activates dendritic cells (DCs) to precisely target the tumor site, reshaping the tumor immune microenvironment, breaking down the immunosuppressive barrier, and allowing CAR-T cells to penetrate deeper into the tumor more efficiently, precisely and persistently killing cancer cells.
100 Clinical Results associated with Claudin18.2-Targeted Activated DC(Frontiergate Biopharm)
100 Translational Medicine associated with Claudin18.2-Targeted Activated DC(Frontiergate Biopharm)
100 Patents (Medical) associated with Claudin18.2-Targeted Activated DC(Frontiergate Biopharm)
100 Deals associated with Claudin18.2-Targeted Activated DC(Frontiergate Biopharm)